ClearPoint Neuro CLPT Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 62.3%+1.1pp | 61.4%+0.5pp | 61.3%+0.9pp | 60.4%+0.6pp | 61.2%+4.1pp | |
| Operating margin | -65.2%+2.1pp | -65.4%-2.5pp | -66.3%-4.5pp | -67.4%-1.3pp | -67.3%+12.8pp | |
| Net margin | -71.6%-7.1pp | -69.1%-8.8pp | -67.4%-7.8pp | -66.2%-2.1pp | -64.5%+14.3pp | |
| EBITDA margin | -63.2%+1.4pp | -63.2%-3.4pp | -63.9%-5.2pp | -64.4%-1.2pp | -64.7%+12.6pp | |
| Free cash flow margin | -65.7%-29.3pp | -66.1%-36.7pp | -40.3%-11.0pp | -34.9%-0.2pp | -36.4%+11.2pp | |
| Returns | ||||||
| Return on equity | -149.7%-73.5pp | -95.6%-14.4pp | -103.1%-34.8pp | -85.7%-25.3pp | -76.2%-14.8pp | |
| Return on assets | -47.1%+2.6pp | -37.3%+8.9pp | -46%-2.8pp | -38.5%-2.6pp | -49.7%-10.0pp | |
| Return on invested capital | -93%+86.2pp | -100.4%+89.1pp | -187%-35.9pp | -170.3%-39.4pp | -179.2%-62.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×-0.1× | 0.5×-0.2× | 0.7×0.0× | 0.6×0.0× | 0.8×+0.3× | |
| Inventory turnover | 3.5×-69.2× | 3.4×-46.8× | 3.9×-36.1× | 4.1×-31.0× | 72.7×+40.0× | |
| Liquidity | ||||||
| Current ratio | 5.8×+2.3× | 5.9×+2.7× | 6.4×+1.8× | 7.3×+4.5× | 3.5×+0.4× | |
| Quick ratio | 4.9×+1.4× | 5.1×+1.9× | 5.6×+1.0× | 6.4×+3.7× | 3.5×+0.4× | |
| Cash ratio | 3.9×+2.0× | 4.4×+2.4× | 4.8×+1.9× | 5.6×+3.7× | 1.8×-0.5× | |
| Leverage | ||||||
| Debt-to-equity | 3.4×+3.2× | 2.1×+1.9× | 2.3×+2.1× | 1.8×+1.4× | 0.2×-0.2× | |
| Debt-to-assets | 0.7×+0.6× | 0.6×+0.5× | 0.6×+0.5× | 0.6×+0.3× | 0.1×-0.1× | |
| Per Share | ||||||
| Book value per share | $0.64-11.6% | $0.99+5.3% | $0.56-46.9% | $0.70-40.3% | $0.72-46.9% | |
| Valuation | ||||||
| Market capitalization | $538.61M+69.2% | $406.96M-4.1% | $619.43M+100% | $328.72M+122% | $328.55M+79.1% | |
| Enterprise value | $565.68M+82.9% | $418.22M+2.6% | $616.78M+112% | $322.46M+150% | $319.6M+97.3% | |
| Price / sales | 13.3×+3.4× | 11×-2.5× | 18×+7.9× | 9.8×+4.5× | 10.2×+3.2× | |
| Price / book | 28.6×+12.7× | 14.5×-2.2× | 39×+28.4× | 16.7×+12.1× | 16.4×+11.1× | |
| EV / sales | 13.9×+4.3× | 11.3×-1.7× | 18×+8.4× | 9.6×+5.0× | 9.9×+3.7× | |
| Free cash flow yield | -5%-1.3pp | -6%-3.8pp | -2.2%+0.6pp | -3.6%+3.0pp | -3.6%+3.2pp | |
| Earnings yield | -5.4%+1.1pp | -6.3%-1.8pp | -3.7%+2.1pp | -6.8%+5.4pp | -6.3%+4.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ClearPoint Neuro's profit margins?
- ClearPoint Neuro (CLPT) runs a 62.3% gross margin and a -65.2% operating margin, with a -71.6% net margin.
- Where do ClearPoint Neuro's ratios come from?
- Every ratio is computed from ClearPoint Neuro's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
